HOME >> MEDICINE >> NEWS
Alliance for Taxpayer Access asks NIH 'Who really owns publicly-funded medical research?'

WASHINGTON In a letter sent Tuesday to National Institutes of Health (NIH) Director, Dr. Elias A. Zerhouni, the Alliance for Taxpayer Access, an informal coalition of stakeholders who support reforms that will make publicly funded biomedical research accessible to the public, expressed deep disappointment after NIH cancelled a planned briefing and announcement on new guidelines. No explanation was given for the cancellation of the announcement.

Advocates had hoped the NIH plan would make peer-reviewed articles on taxpayer-funded research fully accessible and available online at no extra cost to the American public. In the long-awaited Enhanced Public Access Policy, NIH was expected to issue a call to action to each grant recipient to voluntarily submit her or his peer-reviewed scientific research results to PubMed Central at the National Library of Medicine. By making this wealth of federallyfunded research information available to spur innovation and improve health, NIH would work through its grantees to fulfill the 'research compact' that governs every grant of public funds by the agency.

In their letter, the Alliance for Taxpayer Access stated, "We are deeply disappointed by the delay in today's scheduled NIH announcement of its policy on enhanced public access to NIH research. We cannot understand, given the vital interest and importance of this research, especially to Americans awaiting the medical innovation that this public investment fuels, that there is any reason to further delay statement of a clear and open NIH policy."


'"/>

Contact: Colleen Dermody
cdermody@witeckcombs.com
202-887-0500 x18
Witeck Combs
13-Jan-2005


Page: 1

Related medicine news :

1. TB Alliance announces new drug discovery program with GlaxoSmithKline
2. Alliance congratulates Congress and NIH
3. Access to oral health care: Not a level playing field
4. Public interest advocates question NIH Enhanced Access policy
5. Cochlear Implant Increases Access To Mainstream Education
6. Managed-Care Systems Could Save By Eliminating Restricted Access To Dermatologists
7. Answers To Access, Adherence And Tolerance Of Protease Inhibitors
8. Study Shows Child Health Plus Eases Access, But Some Barriers Remain
9. Increased Public Access To Defibrillation Could Prove Potentially Cost-Effective And Life-Saving
10. Specific test key to determine whether or not allergy symptoms are really allergy-related
11. Who really owns publicly-funded medical research?

Post Your Comments:
(Date:5/21/2013)... The Special Olympics Missouri State Summer Games ... the state to Columbia. This state-level event takes place May ... and Columbia College, and at Hickman High School and Town ... kick off at 7:30 p.m. Friday, May 30 with the ... theme, the Parade of Athletes, the culmination of the statewide ...
(Date:5/21/2013)... Venice Beach, Calif. (PRWEB) May 21, 2013 ... to treating a dual diagnosis of Borderline Personality Disorder ... therapy that is proving to be successful for the ... Saturday, June 1, Alina Gorgorian, Ph.D., clinical director ... treatment in Los Angeles, will provide attendees of ...
(Date:5/21/2013)... autism showed significant improvement after six months of simple ... scents, spoons and sponges, according to UC Irvine neurobiologists. ... enrichment led to notable gains in male subjects between ... in Behavioral Neuroscience . , Study co-authors Cynthia ... one of two groups, balanced for age and autism ...
(Date:5/21/2013)... 2013 STAR (Sensory Therapies And ... with sensory challenges and the Sensory Processing Disorder ... and advocacy of Sensory Processing Disorder present Stumbling Blocks ... Improve Quality of Life, a two-hour lecture presented by ... , Learn a method that can aid in ...
(Date:5/21/2013)... Chicago, IL (PRWEB) May 21, 2013 ... business process integration solutions, today announced it is the ... by analyst firm 451 Research. The report, “Adeptia Bets ... in-depth review of the company, its strategy, products, pricing, ... are in need of a framework for integration and ...
Breaking Medicine News(10 mins):Health News:Special Olympics Missouri Athletes Ready to Show Off Skills in Columbia 2Health News:Special Olympics Missouri Athletes Ready to Show Off Skills in Columbia 3Health News:Clearview Treatment Programs Clinical Director to Present on DBT and Substance Abuse at WCSAD 2Health News:Clearview Treatment Programs Clinical Director to Present on DBT and Substance Abuse at WCSAD 3Health News:Enrichment therapy effective among children with autism, UCI study finds 2Health News:STAR Center and SPD Foundation Present a Lecture on Teens and Adults with Sensory Processing Disorder 2Health News:STAR Center and SPD Foundation Present a Lecture on Teens and Adults with Sensory Processing Disorder 3Health News:Adeptia Featured in Recent 451 Research Impact Report 2
(Date:5/21/2013)... May 21, 2013   Accuray Incorporated ... publication of study results involving hundreds of prostate ... System, the most widely used form of prostate ... 304 patients for a median of 5 years, ... that 97 percent of patients with low-risk and ...
(Date:5/21/2013)... Fla. , May 21, 2013  Janssen ... safety results from the global Phase 3 PROMISE ... inhibitor simeprevir (TMC435) led to sustained virologic response ... in 79 percent of treatment-experienced genotype 1 chronic ... including all stages of liver fibrosis, when administered ...
(Date:5/21/2013)... 21, 2013 Abaxis, Inc. (NasdaqGS: ABAX), a ... today that Martin Mulroy , chief ... Dental & Veterinary Conference on Wednesday, May 29, 2013 ... at Le Parker Meridien Hotel in New ... Abaxis develops, manufactures, markets and sells portable blood ...
Breaking Medicine Technology:New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 2New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2
Cached News: